Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
ContributorsBandiera, Carole![orcid](assets/images/orcid.png)
; Locatelli, Isabella; Courlet, Perrine![orcid](assets/images/orcid.png)
; Cardoso, Evelina![orcid](assets/images/orcid.png)
; Zaman, Khalil![orcid](assets/images/orcid.png)
; Stravodimou, Athina![orcid](assets/images/orcid.png)
; Dolcan, Ana; Sarivalasis, Apostolos![orcid](assets/images/orcid.png)
; Zurcher, Jean-Philippe; Aedo-Lopez, Veronica; Dotta-Celio, Jennifer![orcid](assets/images/orcid.png)
; Peters, Solange; Guidi, Monia![orcid](assets/images/orcid.png)
; Wagner, Anna Dorothea; Csajka, Chantal![orcid](assets/images/orcid.png)
; Schneider Voirol, Marie Paule
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
![orcid](assets/images/orcid.png)
Published inCancers, vol. 15, no. 1, 316
Publication date2023-01-03
First online date2023-01-03
Abstract
Keywords
- CDK4/6 inhibitor
- Electronic adherence monitoring
- Interprofessionality
- Medication adherence
- Motivational interviewing
- Neutropenia
- Oral anticancer therapy
- Palbociclib
- Pharmacists
Affiliation
Funding
- Swiss Cancer Research Foundation - [HSR-4077-11-2016]
Citation (ISO format)
BANDIERA, Carole et al. Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study. In: Cancers, 2023, vol. 15, n° 1, p. 316. doi: 10.3390/cancers15010316
Main files (1)
Article (Published version)
Identifiers
- PID : unige:167131
- DOI : 10.3390/cancers15010316
- PMID : 36612312
- PMCID : PMC9818079
Commercial URLhttps://www.mdpi.com/2072-6694/15/1/316
ISSN of the journal2072-6694